Tumor Models Asia 2018 arrived on the market as the only industry-focused preclinical oncology meeting in Asia.

Last year, thought-leaders & decision-makers in pharma and biotech united to explore the most recent developments in the field.

As we see more and more oncology products failing in the clinic, there needs to be a revolution in the way we conduct our preclinical and translational research. Tumor Models Asia is the platform that brings together experts from Pharma and Biotech from across Asia to discuss the vital challenges currently facing the industry.

Last year attendees gained access to insight into the in vivo models that are driving research forward. Including, information on the newest in vivo models, deep dives into the prediction and overcoming of resistance mechanisms, the optimisation of model and target selection rationale; and more.

Why Is This Event For You?

Tumor Models Asia 2018 proved a unique opportunity to hear from speakers that are leading the way in improving the quality of preclinical and translational research, including:

   Innovent Biologics shared how they overcame a novel resistance mechanism

   Crown Bioscience explained the latest updates in their MuPrime Platform for Immuno-Oncology discovery

    EpimAb showed how they have leveraged information from throughout their preclinical phase to better        inform their clinical trial decisions

   The Jackson Laboratory revealed the innovative new Humanized Mouse platforms they have developed